MSA Capital

About The Fund

MSA Capital is a global investment firm established in 2014, managing over USD 2 billion and dedicated to funding highly innovative and disruptive companies in the biotechnology, enterprise-facing core technology, and consumer sectors. With a particular focus on private venture and growth assets, they have crafted a portfolio that includes companies making DNA sequencing accessible to all, aggregating big data for China's largest healthcare systems, and integrating services in the automotive aftermarket. MSA Capital's investment strategy involves engagements from Seed to Series B stages, with an investment sweet spot of around USD 10 million, while their funding range is between USD 1 million and USD 50 million. They are noted in the industry for their long-term investment approach informed by oriental philosophy and modern science, emphasizing a balance and duality that extends to their commitment to social and environmental responsibility. MSA Capital proudly aligns with the United Nations Principles for Responsible Investing and adopts the Institutional Limited Partners Association framework for Diversity, Equity, and Inclusion. They operate with the mission of creating a positive global impact, partnering with institutions and investing in companies that harness business and technology to foster connectivity and inclusivity. Additionally, through their MSA Spark Program, they aspire to foster the creation of the world's most innovative technology companies by collaborating with founders to support startup ventures. Their leadership team includes veterans with decades of experience in investment, operations, and sector-specific expertise across healthcare, biotechnology, and enterprise technology domains. MSA Capital actively shares ideas and resources, seeking to bridge global practices with varied market economies, and engage in partnerships that spur business development and societal benefit.